Dr. Laura Jane Chalmers, MD

Dr. Chalmers practices at Board of Regents of the University of Oklahoma OU Physicians Tulsa in Tulsa, Oklahoma.

Dr. Chalmers' NPI, 1710046156, was assigned on December 8, 2006. Dr. Chalmers graduated from American University of the Caribbean School of Medicine in 2000. Dr. Chalmers holds Oklahoma license 21972.

Dr. Chalmers' primary practice is Board of Regents of the University of Oklahoma OU Physicians Tulsa, at 4444 E 41st St, Tulsa, OK 74135 in Tulsa County. The practice phone is (918) 660-3632.

Dr. Chalmers' primary practice is Board of Regents of the University of Oklahoma OU Physicians Tulsa in Tulsa, Oklahoma. Dr. Chalmers is also affiliated with Council Oak Comprehensive Healthcare. The medical group on file is OU Health. Dmand AI also links Dr. Chalmers to 1 more hospital, 4 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chalmers practices, 4 sites in all. Vendor and product names are available with a free account.

Pediatric endocrinology is Dr. Chalmers' primary specialty in the NPI Registry, under taxonomy code 2080P0205X. Dr. Chalmers is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dr. Chalmers is licensed in Oklahoma.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, osteoporosis, overactive thyroid, parathyroid gland disorder, testicular dysfunction and underactive thyroid among the conditions Dr. Chalmers treats.

CMS data shows 497 Medicare services from Dr. Chalmers across 5 procedure codes in 2024, for 131 Medicare patients. Medicare paid $21,823 for them.

CMS counts 131 Medicare patients who saw Dr. Chalmers in 2024. The largest group is 65 to 74, with 55 patients. 72% of them have high blood pressure, and 60% have high cholesterol. 31% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chalmers' median patient age at 25, with 60% women.

In 2024, Dr. Chalmers wrote 2,378 Medicare Part D claims for 226 patients. 32% of them were for generic drugs. CMS names the drug for 2,018 of them, across 47 drugs with 11 or more claims each, at $805,550 in total drug cost. In 2023, CMS named 1,981 claims across 52 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Chalmers for performance year 2024, reported as part of a group. Dr. Chalmers accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chalmers as offering telehealth.

Dmand AI links 29 papers to Dr. Chalmers, published from 2010 to 2025. 2012 was the busiest year, with 6. The most frequent topics are Cell Movement, Metabolic Syndrome and Obesity. Dr. Chalmers has published most often in J Pediatr Pharmacol Ther. Dr. Chalmers' most frequent co-authors are Kenneth C. Copeland, MD, Sowmya Krishnan, MD and Steven D. Chernausek, MD.

Dmand AI links Dr. Chalmers to 2 clinical trials. Conditions studied include Congenital adrenal hyperplasia due to 21 hydroxylase deficiency, Prader-Willi Syndrome and Adrenal Hyperplasia, Congenital.

CMS Open Payments shows 17 general payments to Dr. Chalmers from 7 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 73% of the total. Tandem Diabetes Care, Inc. paid the most, $2,750. It also lists 8 research payments totaling $34,508 in 2024.

Dr. Chalmers graduated from American University of the Caribbean School of Medicine in 2000. Dr. Chalmers is a member of AACE.

Dr. Chalmers is in network with 14 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.